The Zhitong Finance App learned that on Monday, HCM.US (HCM.US) rose nearly 4% to $12.67. According to the news, on August 17, Huhuang Pharmaceutical issued an announcement announcing that the SAFFRON phase III study on the combination therapy of voraxa (sevolitinib) and taresa (ositinib) had achieved positive front-line results. The study targeted EGFR mutant non-small cell lung cancer patients whose disease progressed after previous treatment with Teresa and whose tumors were accompanied by high levels of MET overexpression or amplification. Research results showed that combination therapy showed statistically and clinically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to platinum-type dual-agent chemotherapy.

Zhitongcaijing · 2d ago
The Zhitong Finance App learned that on Monday, HCM.US (HCM.US) rose nearly 4% to $12.67. According to the news, on August 17, Huhuang Pharmaceutical issued an announcement announcing that the SAFFRON phase III study on the combination therapy of voraxa (sevolitinib) and taresa (ositinib) had achieved positive front-line results. The study targeted EGFR mutant non-small cell lung cancer patients whose disease progressed after previous treatment with Teresa and whose tumors were accompanied by high levels of MET overexpression or amplification. Research results showed that combination therapy showed statistically and clinically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to platinum-type dual-agent chemotherapy.